← All organizations
Highest phase reached
Phase 3
First clinical trial
Dec 1, 2010Last known activity
Aug 31, 2025
Timeline
2000s
- Jan 1, 2004
Grupo Espanol de Tumores Neuroendocrinos (GETNE)— Founded
Drugs by trial phase (21 distinct, 17 trials)
Phase 3 (7 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma, Follicular
- Adenoma, Islet Cell
- Carcinoma
- Carcinoma, Islet Cell
- Carcinoma, Neuroendocrine
- Carcinoma, Papillary
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Gastrointestinal Neoplasms
- Lung Neoplasms
- Neoplasms
- Neuroendocrine Tumors
- Pancreatic Neoplasms
- Paraganglioma
- Pheochromocytoma
- Thyroid Cancer, Papillary
- Thyroid Carcinoma, Anaplastic
- Thyroid Diseases
- Thyroid Neoplasms
Recent trials (20)
- NCT07061080Lead sponsorPhase 2Aug 31, 2025
- NCT06878664Lead sponsorPhase 3Jun 12, 2025
- NCT06235216Lead sponsorPhase 2Sep 13, 2024
- NCT05918302Lead sponsorPhase 3Oct 27, 2023
- NCT05660954Lead sponsorPhase 2Jan 31, 2023
- NCT04400474Lead sponsorPhase 2Oct 31, 2020
- NCT03980925Lead sponsorPhase 2Sep 30, 2019
- NCT03753919Lead sponsorPhase 2Apr 2, 2019
- NCT03095274Lead sponsorPhase 2Mar 1, 2017
- NCT02713763Lead sponsorPhase 2Apr 1, 2016
- NCT02678780Lead sponsorPhase 2Oct 1, 2015
- NCT02806648Lead sponsorPhase 2May 1, 2015
- NCT02402062Study chairPhase 2Feb 1, 2015
- NCT02402062Lead sponsorPhase 2Feb 1, 2015
- NCT02246127Lead sponsorPhase 3Oct 27, 2014
Details
- Founded
- Barcelona, ES Jan 1, 2004
- Last known activity
- Aug 31, 2025